Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329727 | 0.94 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2DRD4KDM4EMAPT | |
| SCHEMBL4326335 | 0.93 | DRD4 (0.53) | ALDH1A1SMN1; SMN2DRD4DRD2SIGMAR1 | |
| SCHEMBL4329231 | 0.93 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2DRD4DRD2SIGMAR1 | |
| SCHEMBL4464690 | 0.93 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2DRD4DRD2SIGMAR1 | |
| SCHEMBL4463803 | 0.93 | GAA (0.48) | ALDH1A1SMN1; SMN2DRD4DRD2SIGMAR1 | |
| SCHEMBL4455998 | 0.90 | HTR1A (0.53) | ALDH1A1SIGMAR1KDM4EGAAKCNH2 | |
| SCHEMBL4326085 | 0.90 | KCNH2 (0.53) | ALDH1A1SMN1; SMN2DRD4DRD2MAPT | |
| SCHEMBL4326331 | 0.89 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2DRD4DRD2KDM4E | |
| SCHEMBL4328173 | 0.89 | ALDH1A1 (0.47) | ALDH1A1DRD4DRD2SIGMAR1 | |
| SCHEMBL4332404 | 0.87 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2DRD4DRD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | ALDH1A1 1785/4885SMN1; SMN2 1220/4885DRD4 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.